admin

BioIT Solutions, Inc.

Michael Fannon is the President and Founder of BioIT Solutions, Inc. in Silver Spring, Maryland. Mike has over 20 years of experience in the design, development and management of systems focused on Biotechnology research, development, clinical trials and product manufacturing. Mike is the chief architect of the BioIT Solutions Portal Products that form the foundation of logical, consistent and responsive systems tailored to solve complex data management problems. Mike was VP and Chief Information Officer of Human Genome Sciences, Inc. from 1994 through 2005 where he managed the design and implementation of computerized systems to support HGS’s high-volume laboratory data collection, biological research, clinical data management, product development, manufacturing and business operations. Prior to joining HGS, Mike was the founder and president of TSI Consulting and held a series of technical and management positions with Martin Marietta’s Information Systems Group. Mike earned an MBA in Operations Analysis from The American University, and a Bachelor’s degree in Physics from Rollins College in Winter Park, Florida.

NaviMed Capital

Mr. Chan started working with NaviMed Capital in 2012 where he focuses on investing in privately held healthcare companies. Prior to NaviMed, Mr. Chan was part of the healthcare investment team at Siemens Venture Capital. Based out of Boston and Beijing, he evaluated and sourced healthcare deals worldwide, performed research on various market sectors and supported portfolio companies. Mr. Chan also held an investment role at SAC Capital and a marketing role at Medtronic Cardiovascular. Mr. Chan started his career developing a molecular diagnostic technology at a venture backed company. At Siemens Venture Capital, Mr. Chan was a Board Observer at MD Datacor and actively involved in the following investments: BioImagene, RadPharm, China Diagnostics, U-Systems and Cylex. Mr. Chan was a founding fellow of the Startup Leadership Program in 2007 and has mentored various start-ups to raise over $30 million in venture financing to date. Mr. Chan holds a B.S. from Johns Hopkins University and an M.B.A. from the Wharton School at the University of Pennsylvania.

Sr. Director, Scientific Services, Emergent BioSolutions

Moustapha El-Amine is a Senior Director and the Head of the Scientific Services (Affairs) department at Emergent Biosolutions Inc.  His role is to lead and manage technical due diligence activities associated with merger and new product acquisition activities and to develop corporate processes to evaluate internal preclinical and research programs in oncology, autoimmunity and infectious diseases.  He also assesses the development status and scientific progress of all preclinical and research programs in all platforms at Emergent BioSolutions.  In his role Dr. El-Amine continuously monitors and evaluates new technologies and selects those that are of interest to Emergent Biosolutions.  Before Joining Emergent Dr. El-Amine was a Principal Investigator at Dynport Vaccines (DVC, Inc.) leading a Vaccine program for DoD and before that he lead the iLT patch vaccine program at Iomai corp (Later Acquired by Intercell).  Dr. El-Amine has a Bachelor degree in Biology from the American University of Beirut (AUB, Beirut, Lebanon), a Masters in Molecular Endocrinology from Laval University (Quebec, Canada) and a PhD in Cell biology (Immunology) from Sherbrooke University (Sherbrooke, Canada).  Dr. El-Amine moved from Canada to Rockville, Maryland in 1997 to pursue postdoctoral training in gene-therapy/immunology at the American Red Cross, Jerome Holland Laboratories in David Scott’s Lab.  Dr. El-Amine is completing an MBA at the Carey School of Business at Johns Hopkins University.

President, Chief Executive Officer and Director, BioMarker Strategies

As Principal of Policy Advocates, Inc., from 1995-2001, Mr. Parrott’s clients included HGS, Bristol-Myers Squibb, Ciba-Geigy, Diversa, Genentech, HealthCare Ventures, Hoffmann-La Roche, Western Digital and Wyeth. During this period, he helped take public both 3-Dimensional Pharmaceuticals, subsequently acquired by Johnson & Johnson, and InforMax, Inc., subsequently acquired by Invitrogen. He previously held senior policy and corporate communications management positions with Bristol-Myers Squibb Company (1979-1995), American Hospital Supply Corporation (1976-1979), and Walgreen Company (1973-1976).

Mr. Parrott has helped launch important therapeutic products in immunology, oncology, infectious disease and pain relief, and has helped bring two prescription products over the counter. He received his B.A. from the University of South Florida and attended graduate school as a University Fellow at Northwestern University. Mr. Parrott currently serves as Chair of the Board of Directors of Maryland Health Care Product Development Corporation, Senior Advisor to the Maryland Life Sciences Advisory Board, and as a Director of the Tech Council of Maryland and MdBio. He formerly served as Chair of the Biotechnology Industry Organization (BIO) Committee on Outreach and Alliance Development, Chair of the Rx Partners health care reform coalition, Founding Trustee of the Foundation for Genetic Medicine, and Trustee of the Committee for Economic Development.